TauRx exists to solve one of the world’s biggest challenges – beating Alzheimer’s and other degenerative brain diseases via a completely new approach Read more
We combine pioneering research and drug development Read more
Our protein aggregation inhibitors aim to halt disease progression by targeting the underlying pathology of dementia Read more
Protein aggregation inhibitor LMTX® is a patented novel chemical entity currently in development for the prevention of Alzheimer’s and bvFTD Read more
Phase 3 trials for LMTX® now completed - over 1,900 patients, across 20 countries Read more
An Introduction to Alzheimer’s Disease
This World Alzheimer’s Day, watch our new video explaining how the symptoms of Alzheimer’s disease develop, why the disease has such an impact on patients and carers and what TauRx is doing to help.
The tau tangle pathway is a key driver of Alzheimer’s disease leading to loss of neuronal function, spread of pathology and clinical symptoms. Find out more
TauRx’s tau aggregation inhibitors are the outcome of nearly 30 years of research, preclinical and clinical investigations. Find out more
An abstract from the second of TauRx's two Phase 3 trials in Alzheimer's disease was presented at CTAD 2016 on 8th December. Find out more
TauRx and LMTX
Claude Wischik, TauRx CEO, discusses the clinical development of LMTX, and what the recent Phase 3 results mean for TauRx’s on-going development programme.
Claude Wischik explores TauRx’s broad-based research activities including its pioneering work on both the treatment and early diagnosis of AD.
Alzheimer’s Disease and Tau Pathology
Claude Wischik talks about how the Alzheimer’s research landscape has evolved over the past thirty years and the impact of the disease on patients and their families.